3billion to Host Conferences on Genomic Testing for Rare Diseases in Egypt
- Events in Cairo on November 19 and in Alexandria on November 21 are expected to draw around 100 specialists from leading Egyptian universities and hospitals.
- Clinicians will share real-world cases covering rare disease diagnosis using whole-exome sequencing (WES), follow-up testing, and patient management.
- The conferences aim to strengthen collaboration with Egyptian clinicians and support the expansion of 3billion’s diagnostic services across the Middle East and North Africa.

SEOUL, South Korea, November 17, 2026 — 3billion, Inc., an AI-powered genetic diagnostics and drug discovery company led by CEO Changwon Keum, announced that it will host clinical conferences in Cairo on November 19 and in Alexandria on November 21. Titled “A Clinical Dialogue on Genetic Testing in Egypt,” the program will bring local clinicians together to share their experience using genomic testing to diagnose rare diseases and guide follow-up care. The events are part of 3billion’s efforts to strengthen collaboration with Egyptian healthcare providers and expand its presence in the Middle East and North Africa (MENA).
This is the first clinical conference 3billion has organized in Egypt. Around 100 neurologists, pediatricians, ophthalmologists, and other specialists from leading Egyptian universities and hospitals, including Cairo University and Alexandria University, are expected to attend. Local clinical experts and 3billion’s medical team will draw on cases involving whole-exome sequencing (WES) to introduce diagnostic technologies and services and show how they are used in practice. They will also discuss cases submitted in advance.
The conference aims to expand the clinical use of genomic diagnostics, encourage clinicians to share their experiences, and strengthen partnerships. 3billion is co-hosting the event with Mass Diagnostics, which provides guidance on genetic testing and supports specimen logistics in Egypt.
With a population of more than 100 million, Egypt is one of 3billion’s priority markets in MENA. The company’s expansion in Egypt is gaining momentum as the country strengthens its infrastructure for diagnosing and treating rare diseases. Under the 2026–2030 National Strategy for Rare Diseases, Egypt’s Ministry of Health and Population and the Egyptian Drug Authority (EDA) are working to improve clinicians’ diagnostic capabilities, establish regional centers for genetic diagnosis and a patient registry, support research, and mobilize funding.
3billion expects these efforts to encourage wider use of genomic testing in Egypt and create opportunities to work with local healthcare institutions. The conferences will help clinicians select and use genomic tests. 3billion plans to build on these exchanges to generate new test referrals and partnerships across specialties, reach new customers, and grow revenue across MENA, where more than 2.8 million people are estimated to live with rare diseases.
“For genomic testing to help more patients receive a diagnosis, clinicians need to understand the tests and know how to use them in practice,” said Sookjin Lee, Chief Business Officer at 3billion. “We aim to earn the trust of local clinicians by supporting them from test selection through follow-up care. Our goal is to help more healthcare providers across the Middle East and North Africa use 3billion’s tests in patient care.”
“For genomic testing to help more patients receive a diagnosis, clinicians need to understand the tests and know how to use them in practice,” said Sookjin Lee, Chief Business Officer at 3billion. “We aim to earn the trust of local clinicians by supporting them from test selection through follow-up care. Our goal is to help more healthcare providers across the Middle East and North Africa use 3billion’s tests in patient care.”
3billion provides genetic testing for rare diseases in 10 countries across the Middle East and Africa, including the United Arab Emirates. In 2025, the company signed an agreement to supply GEBRA, its AI-powered variant interpretation software, to the Mohammed VI Foundation for Sciences and Health (FM6SS) in Morocco. The software supports rapid genomic testing and variant interpretation in a neonatal intensive care unit. 3billion also provides testing through a local partner in Egypt as it expands its genomic testing and AI software businesses across MENA.
Get exclusive rare disease updates
from 3billion.

3billion Inc.
3billion is dedicated to creating a world where patients with rare diseases are not neglected in diagnosis and treatment.




